TREATMENT OF NON-RESECTABLE PANCREATIC CANCER WITH 5-FLUOROURACIL, LEUCOVORIN AND MITOMYCIN-C:ONE CASE SHOWED COMPLETE REMISSION FOR 36 MONTHS
スポンサーリンク
概要
- 論文の詳細を見る
Pancreatic cancer has a dismal prognosis because most lesions are unresectable where as adjuvant and palliative chemotherapy exhibits poor results.Six patients with locally unresectable pancreatic cancer were treated with mitomycin-C (MMC) 8mg/m2 on day 1 and 5-FU 375mg/m2 and LV 20mg/m2 on days 1 to 5. Treatment cycles were repeated every four weeks if the patient's general condition permitted. All patients had measurable, histologically proven adenocarcinoma and had not undergone prior chemotherapy.Three patients underwent hepaticojejunostomy whilst choledochal stents were endoscopically inserted in two patients. No significant side effects of grade 3 or 4 were observed. Five of six patients who received an average of 5 treatment cycles died of their disease with a medial survival of 8.9 months. The remaining patient received 12 treatment cycles and 8 additional treatments without mitomycin-C and exhibited a complete remission for 36 months.Our data suggest that MMC plus 5-FU and leucovorin is a tolerable regimen and has promising effects. Further prospective studies are needed.
- 日本癌病態治療研究会の論文
日本癌病態治療研究会 | 論文
- Current status of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) targeting cancer therapy
- Endoscopic Mucosal Resection (EMR) for Colorectal Lesions and Lesion-lifted Condition as an Indicator of the Tumor Invasion
- NOVEL APPROACH TO IMMUNOTHERAPY FOR EPITHELIAL CANCERS, BONE AND SOFT-TISSUE SARCOMAS
- Extracellular heat shock proteins (eHSPs) pilot exogenous antigen into cross-presentation pathway: A superguide from extracellular world to intracellular tour
- Preoperative body mass index and outcomes of gastric cancer patients